Weeks after the Food and Drug Administration approved the Alzheimer's drug Aduhelm, doctors are struggling to figure out who should get the drug and how to use it safely.
Some patients who have had COVID-19 develop symptoms resembling early Alzheimer's. Researchers are trying to figure out whether these people are more likely to develop the disease itself.
A plaque-busting Alzheimer's drug called Aduhelm has yet to prove it can preserve memory and thinking. Even so, its approval by the Food and Drug Administration is making some patients opitimistic.
In his resignation letter, Dr. Aaron Kesselheim calls it "probably the worst drug approval decision in recent U.S. history." An FDA official says the agency found the benefits outweighed the risks.
The FDA has until Monday to decide whether to approve the first new Alzheimer's drug in nearly two decades. Two big studies of the drug produced conflicting results.
Nonwhite Americans looking for care for a loved one are much more likely than whites to encounter discrimination, language barriers, and providers who lack cultural competence, a new report finds.
Many senior citizens entered their golden years with more debt than previous generations, and now they're struggling financially as they try to provide care for an ailing relative during the pandemic.
Viewers worldwide are responding to a moving video of Marta C. González, a former dancer afflicted with dementia. But critics are questioning whether González is who the clip makers claim she is.
Researchers launched a major study of an experimental Alzheimer's drug this summer. They also learned a lot about how to protect participants who must make frequent visits to a medical center.